From Big Data to Measurable Outcomes: Aligning Stakeholder Needs for Value Based Contracts

This white paper is part of DIA’s White Paper Library
Pharmaceutical companies and payers typically have several goals when considering an outcomes-based contract. For pharmaceutical companies, goals may include improving a drug’s position on the preferred drug list of a health plan, accelerating the availability of new treatments on a formulary, reaching an agreement on a reimbursement framework when some longer-term benefits are still unproven, and getting drugs to the market more quickly. For payers, costs are a primary concern, particularly for high-cost new therapies that are unproven in the real world. Payers are also interested in improving allocation of resources towards their members most likely to receive benefit.
Download Now!
INTERESTED IN PUBLISHING?

For more information on publishing your White Paper with DIA, including schedule and pricing, please contact JT Hroncich at JT@adboomadvertising.com.